Warren is the former senior science editor of TheBody.com and TheBodyPRO.com. He started out as an editorial intern in 2008.
He has been awarded journalist fellowships from the HIV Research for Prevention conference, and the Logan Science Journalism program.
He is a member of the Association of Health Care Journalists, the National Association of Science Writers, Science Writers in New York, and Asian American Journalists Association.
Warren is a native New Yorker, born in Manhattan and raised in Queens.
Follow Warren on Twitter: @WarrenAtTheBody.
Warren does not have any disclosures or conflicts of interest to report, as of June 20, 2017.
Categories Covered:HIV Treatment Strategies, FDA-Approved HIV Medications, Efavirenz (Sustiva, Stocrin), Abacavir (Ziagen), Stribild (Elvitegravir/Cobicistat/FTC/Tenofovir), Tenofovir Disoproxil Fumarate (Viread), Doravirine (Pifeltro), Etravirine (Intelence), Rilpivirine (Edurant), Ibalizumab (Trogarzo), Adverse Events, Comorbidities, and HIV, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate (Stribild), Cobicistat/Emtricitabine/Elvitegravir/Tenofovir Alafenamide (Genvoya, E/C/F/TAF), Providing Quality HIV Care, Legal Issues, HIV-Related Policy Issues, HIV Treatments in Development, Latinx People, PrEP (HIV Pre-Exposure Prophylaxis), Pregnancy, Childbirth, and HIV, Gay Men, HIV Stigma and Discrimination, HIV Drugs In Development, HIV Treatment and Medical Care, HIV Policy and Advocacy, HIV Education and Risk Management, HIV Prevention Methods, HIV Epidemiology, First-Line HIV Treatment, HIV Care and Services Outside the US, Managing People Newly Diagnosed With HIV, HIV Care Continuum, Dolutegravir (Tivicay), Physical Health Issues, Mental Health, Women, Curing HIV, African-Americans, Managing HIV Drug Resistance, HIV Testing, HIV Prevention and Transmission, Switching or Stopping HIV Treatment, U=U (Undetectable Equals Untransmittable, i.e. HIV Treatment as Prevention), HIV Testing, HIV in Arts and Entertainment, HIV in Film, TV, and Media, Cancer and HIV, Starting HIV Treatment and Medical Care, Managing Long-Term HIV Survivors, HIV Case Management and Social Work, HIV Advocates in the Spotlight, HIV/AIDS Outside the U.S., HIV in Specific Countries, Meeting the Costs of HIV Care, Emtricitabine/Rilpivirine/Tenofovir Alafenamide (Odefsey), Emtricitabine (FTC, Emtriva), HIV Advocacy and Activism, History of HIV/AIDS, Primary Care of People With HIV, HIV Basic Science and Pathogenesis, People Under 30, Newly Diagnosed, Myths About HIV/AIDS, Vaccines and Microbicides for HIV, Emtricitabine/Tenofovir Alafenamide (Descovy), Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada), Non-HIV Sexually Transmitted Infections, Liver Issues and HIV, Lopinavir/Ritonavir (Kaletra), Lamivudine (3TC, Epivir), Cobicistat/Darunavir (Prezcobix), HIV, Discrimination, and Law, Understanding HIV-Related Lab Tests, Regional/Global Anti-HIV Efforts, Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy, B/F/TAF), Atazanavir/Cobicistat (Evotaz), Finding HIV Support Groups and Services, PrEP (HIV Pre-Exposure Prophylaxis), Nutrition and Fitness, Pediatric HIV Care, Managing Primary/Acute HIV Infection, Living Well With HIV, Bone Problems and HIV, Flu (Influenza), Colds, and HIV, Switching or Stopping HIV Treatment, HIV in the Arts, People Over 50, PEP (HIV Post-Exposure Prophylaxis), Disclosing Your HIV Status, HIV and Mental Health Care
Long-acting injectable treatment takes another step closer to being a real-world option for people living with HIV, with new study results presented at IAS 2017.
Officials at the IAS 2017 opening session gave speeches about science, research and innovation, but it was the activists who stole the show.
The thought of getting an HIV test can be intimidating or scary. But with a little bit of knowledge about what to expect and basic information on HIV, you can be more confident and comfortable when you get tested.
Today is National HIV Testing Day -- a day when we emphasize the importance of knowing your HIV status. Knowing your status so you can act on it is part of why HIV testing remains important to this day.
Life expectancy for a person living with HIV who is on antiretroviral therapy increased by about 10 years between 1996 and 2013, according to a new study.
You may have heard about the "HIV cure with gene editing in animals" story. Here's some help making sense of the story, including what's true or not, and what to get excited about.
Starting HIV treatment soon after diagnosis may reduce the risk of developing HIV-related cancer by 74%, according to a recent study.
Some HIV journalists got a nasty surprise recently when they attempted to register for NMAC's National HIV PrEP Summit.